Stem Cell Therapeutics Corp., of Toronto, said it intends to file a prospectus supplement in certain Canadian provinces for its previously announced offering, consisting of up to 14 million units – each comprising one common share and one common share purchase warrant – priced at C25 cents (US24 cents) apiece...at the same unit price.

The ESS system is designed to stimulate progenitor stem cells in the bone marrow...Also, 93 percent of people in that dose group showed no clinical symptoms of influenza after three days of treatment, compared to 41 percent of people in the placebo group

In total, Ablynx has five products in clinical development and six in preclinical development, of which five are with partners...Funds will be used to advance development programs across Bionomics' pipeline, including BNC375, Bionomics' drug candidate for the treatment of Alzheimer's disease and other conditions where memory is significantly compromised and Bionomics' cancer stem cell directed drug candidate BNC101...At the completion of the capital raising, Bionomics will have approximately $26

In conjunction with the changes in its clinical program, the company said it reduced its work force by 50 percent and outsourced noncritical research and development functions...Kiadis Pharma BV, of Amsterdam, the Netherlands, said it received a No Objection Letter from Canadian regulators to proceed with a Phase II study testing ATIR, a cell-based product designed to enable stem cell transplantation from mismatched family donors

The primary objectives include the evaluation of adverse events and the evaluation of six-month clinical response...Chimerix Inc., of Research Triangle Park, N.C., presented data during the Allogeneic Transplants Poster Session at the BMT Tandem Meetings in Salt Lake City over the weekend, including data from a Phase II study testing CMX001 for the prevention of cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation...Edison Pharmaceuticals Inc., of Mountain View, Calif

Amicus Therapeutics Inc., of Cranbury, N.J., reported positive results from clinical and preclinical studies of the pharmacological chaperone AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease at the Lysosomal Disease Network World Symposium...Based on those results, the company plans to initiate a repeat-dose clinical study in the third quarter of 2013 to evaluate an intravenous formulation of AT2220 co-administered with Myozyme/Lumizyme...CDX-301 is a cytokine that stimulates the

Advanced Cell Technology Inc. (ACT), of Marlborough, Mass., said its clinical partner, the University of California, Los Angeles (UCLA), received FDA approval for its investigational new drug application...The ALS Therapy Development Institute, of Cambridge, Mass., received FDA approval to conduct a clinical trial of TDI-132, or fingolimod (Gilenya, Novartis AG) in amyotrophic lateral sclerosis (ALS...TG Therapeutics Inc., of New York, amended its Phase I/II study of single agent ublituximab to

Apceth GmbH and Co., of Munich, Germany, finished a second round of financing for its adult mesenchymal stem cells product, Agenmestencel-T. The 2.5-year round was carried out through the German Federal Ministry of Education and Research as part of the Munich Biotech Cluster initiative knowns as M4 Personalized Medicine and Targeted Therapies...Funds will be used to advance clinical activity according to its recently disclosed 2013 plan

Portola Pharmaceuticals Inc., of South San Francisco, inked a clinical collaboration with Janssen Pharmaceuticals Inc., a unit of New Brunswick, N.J.-based Johnson & Johnson, and Bayer AG, of Leverkusen, Germany, to evaluate the safety of PRT4445, an antidote for Factor Xa inhibitors, in healthy volunteers to have been administered oral anticoagulant Xarelto (rivaroxaban...The dose-escalation study will evaluate safety, tolerability and efficacy as determined by RECIST criteria and the company's

BrainStorm Cell Therapeutics Inc., of New York, began treating its first patient in a Phase IIa trial of its stem cell therapy in amyotrophic lateral sclerosis...The trial will assess safety and clinical benefit of various dose levels of cells

DelMar is working on a cancer drug pipeline, including lead asset VAL-083, which is in clinical trials in refractory glioblastoma multiforme...Gross proceeds totaled $38.2 million and will support the firm's work on therapies targeting cancer stem cells. (See BioWorld Today, Jan. 30, 2013

Medivir AB, of Stockholm, Sweden, said it entered a nonexclusive collaboration between Janssen Pharmaceuticals Inc., part of Johnson & Johnson, of New Brunswick, N.J., and Idenix Pharmaceuticals Inc., of Cambridge, Mass., for the clinical development of an all-oral (interferon-free) direct-acting antiviral (DAA) hepatitis C (HCV) combination therapy...Repros Therapeutics Inc., of The Woodlands, Texas, provided a revised date for expected clinical results from the first pivotal trial, ZA-301, of

Bone Therapeutics will also move an allogeneic version of the product into a clinical trial in patients with delayed union fractures later this year...If the clinical data are good, it will be able to marshal strong pharmacoeconomic arguments...KAHR will receive NIS4.95 million to assist in developing its SCP (signal converter proteins) platform technology that enables the creation of protein-based drugs with two active sites.

BioTime Inc., of Alameda, Calif., said it submitted a clinical investigation protocol to European regulatory authorities for approval to initiate studies for its Renevia stem cell delivery platform

Secondary endpoints also were met, including the clinical cure rate at end of treatment day 10 to day 14 (88.9 percent) and test of cure at day 21 to day 28 (100 percent...That allows Lorus to initiate a biomarker clinical investigation to further explore the effects of the drug at relevant doses determined in the trial...The complete clinical study report for the interim analysis would be supplied to the FDA during the review within 60 days of the resubmission

Acasti Pharma Inc., of Laval, Quebec, said it achieved significant progress in two ongoing clinical studies with CaPre for lipid management...The registrational Phase II double-blind, placebo-controlled clinical study has completed the first of two interim analyses...It has been delayed due to the need for further patient recruitment after the approved clinical trial amendment to add an additional 4-g/day CaPre treatment group, following an FDA recommendation to evaluate the effect of a 4-g dose

In Japan, 20 percent of the approved clinical trials using stem cells deploy Cytori products...Most stem-cell companies treat 5, 10, 20 patients

Spectrum Pharmaceuticals Inc., of Henderson, Nev., presented clinical data at the recent American Society of Hematology meeting in Atlanta for cancer drug Zevalin (yttrium-90-ibritumomab tiuxetan), including results from a Phase II study showing that Zevalin plus BEAM chemotherapy (carmustine, etoposide, cytarabine and melphalan) prior to autologous stem cell transplantation in refractory non-Hodgkin's diffuse large B-cell lymphoma produced a two-year overall survival rate of 65 percent and a

with experience and expertise in stem cell clinical trials studying treatments for cardiovascular heart diseases...A further nine patients are expected to be enrolled at three oncological centers in the U.S. Based on the results, the company will implement a clinical study aimed at evaluating the effects of Reparixin, an inhibitor of the CXCR1 receptor activated by chemokine interleukin 8, in oral monotherapy on cancer stem cells and on tumor microenvironment for the treatment of women with early